Evaluation of serum markers in the LRF CLL4 trial: β₂-microglobulin but not serum free light chains, is an independent marker of overall survival

References

• Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124:49–62.
   PubMed Web of Science ®Google Scholar
• Pepper C, Majid A, Lin TT, et al. Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol. 2012;156:499–507.
   PubMed Web of Science ®Google Scholar
• Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood. 2006;107:2889–2894.
   PubMed Web of Science ®Google Scholar
• Wierda WG, O'Brien S, Wang X, et al. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011;29:4088–4095.
   PubMed Web of Science ®Google Scholar
• Fink A, Pflug N, Busch R, et al. Serum factors predict therapeutic outcome in patients with chronic lymphocytic leukemia treated in the CLL8 Trial of the German CLL Study Group (GCLLSG). Blood (Suppl). 2010;116:918.
   Google Scholar
• Delgado J, Pratt G, Phillips N, et al. Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. Br J Haematol. 2009;145:801–805.
   PubMed Web of Science ®Google Scholar
• Matthews C, Catherwood MA, Morris TC, et al. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. Eur J Haematol. 2006;77:309–317.
   PubMed Web of Science ®Google Scholar
• Kallander CF, Simonsson B, Hagberg H, et al. Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer. 1984;54:2450–2455.
   PubMed Web of Science ®Google Scholar
• Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood. 1999;93:1732–1737.
   PubMed Web of Science ®Google Scholar
• Magnac C, Porcher R, Davi F, et al. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia. 2003;17:133–137.
   PubMed Web of Science ®Google Scholar
• Konoplev SN, Fritsche HA, O'Brien S, et al. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. Am J Clin Pathol. 2010;134:472–477.
   PubMed Web of Science ®Google Scholar
• Meuleman N, Stamatopoulos B, Dejeneffe M, et al. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients. Leukemia. 2008;22:1882–1890.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Willheim M, Hilgarth M, et al. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J Clin Oncol. 1994;12:2146–2152.
   PubMed Web of Science ®Google Scholar
• Sarfati M, Chevret S, Chastang C, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood. 1996;88:4259–4264.
   PubMed Web of Science ®Google Scholar
• Molica S, Levato D, Dell'Olio M, et al. Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis. Haematologica. 1996;81:428–433.
   PubMed Web of Science ®Google Scholar
• Knauf WU, Ehlers B, Mohr B, et al. Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemia. Blood. 1997;89:4241–4242.
   PubMed Web of Science ®Google Scholar
• Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2008;142:202–215.
   PubMed Web of Science ®Google Scholar
• Pratt G, Harding S, Holder R, et al. Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. Br J Haematol. 2009;144:217–222.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Cerhan JR, Katzmann JA, et al. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood. 2011;118:2821–2826.
   PubMed Web of Science ®Google Scholar
• Morabito F, De Filippi R, Laurenti L, et al. The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood. 2011;118:6353–6361.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Oscier D, Wade R, Davis Z, et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica. 2010;95:1705–1712.
   PubMed Web of Science ®Google Scholar
• Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109:4679–4685.
   PubMed Web of Science ®Google Scholar
• De Filippi R, Russo F, Iaccarino G, et al. Abnormally elevated levels of serum free-immunoglobulin light chains are frequently found in classic Hodgkin lymphoma (cHL) and predict outcome of patients with early stage disease. Blood (Suppl). 2009;114:267.
   Google Scholar
• Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol. 2010;28:773–779.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Katzmann JA, Kyle RA, et al. Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. Mayo Clinic Proc. 2012;87:517–523.
   PubMed Web of Science ®Google Scholar
• Anandram S, Assi LK, Lovatt T, et al. Elevated, combined serum free light chain levels and increased mortality: a 5-year follow-up, UK study. J Clin Pathol. 2012;65:1036–1042.
   PubMed Web of Science ®Google Scholar